Evidence map›Paper›PMID 36364890›Full record

ArticleNutrients2022

Machine Learning Models Predicting Cardiovascular and Renal Outcomes and Mortality in Patients with Hyperkalemia.

Eiichiro Kanda, Suguru Okami, Shun Kohsaka, Masafumi Okada, Xiaojun Ma, Takeshi Kimura, Koichi Shirakawa, Toshitaka Yajima

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Eiichiro KandaMedical Science, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan.
Suguru OkamiCardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Tower B Grand Front Osaka, 3-1 Ofukacho, Kita-ku, Osaka 530-0011, Japan.
Shun KohsakaDepartment of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku-ku, Tokyo 160-8582, Japan.ORCID 0000-0003-3779-2972
Masafumi OkadaIQVIA Solution Japan K.K., Keikyu dai-ichi Building, 4-10-18 Takanawa, Minato-ku, Tokyo 108-0074, Japan.
Xiaojun MaIQVIA Solution Japan K.K., Keikyu dai-ichi Building, 4-10-18 Takanawa, Minato-ku, Tokyo 108-0074, Japan.
Takeshi KimuraReal World Data Co., Ltd., 76 Nakanocho, Nakagyo-ku, Kyoto 604-0086, Japan.
Koichi ShirakawaCardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Tower B Grand Front Osaka, 3-1 Ofukacho, Kita-ku, Osaka 530-0011, Japan.
Toshitaka YajimaCardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Tower B Grand Front Osaka, 3-1 Ofukacho, Kita-ku, Osaka 530-0011, Japan.
AstraZeneca (Japan) · JPKawasaki Medical School · JPKeio University Hospital · JP

Funding

AstraZeneca (Japan) Not a Grant Number
6 · The paper itself

Abstract

Hyperkalemia is associated with increased risks of mortality and adverse clinical outcomes. The treatment of hyperkalemia often leads to the discontinuation or restriction of beneficial but potassium-increasing therapy such as renin-angiotensin-aldosterone inhibitors (RAASi) and high-potassium diet including fruits and vegetables. To date, limited evidence is available for personalized risk evaluation in this heterogeneous and multifactorial pathophysiological condition. We developed risk prediction models using extreme gradient boosting (XGB), multiple logistic regression (LR), and deep neural network. Models were derived from a retrospective cohort of hyperkalemic patients with either heart failure or chronic kidney disease stage ≥3a from a Japanese nationwide database (1 April 2008−30 September 2018). Studied outcomes included all-cause death, renal replacement therapy introduction (RRT), hospitalization for heart failure (HHF), and cardiovascular events within three years after hyperkalemic episodes. The best performing model was further validated using an external cohort. A total of 24,949 adult hyperkalemic patients were selected for model derivation and internal validation. A total of 1452 deaths (16.6%), 887 RRT (10.1%), 1,345 HHF (15.4%), and 621 cardiovascular events (7.1%) were observed. XGB outperformed other models. The area under receiver operator characteristic curves (AUROCs) of XGB vs. LR (95% CIs) for death, RRT, HHF, and cardiovascular events were 0.823 (0.805−0.841) vs. 0.809 (0.791−0.828), 0.957 (0.947−0.967) vs. 0.947 (0.936−0.959), 0.863 (0.846−0.880) vs. 0.838 (0.820−0.856), and 0.809 (0.784−0.834) vs. 0.798 (0.772−0.823), respectively. In the external dataset including 86,279 patients, AUROCs (95% CIs) for XGB were: death, 0.747 (0.742−0.753); RRT, 0.888 (0.882−0.894); HHF, 0.673 (0.666−0.679); and cardiovascular events, 0.585 (0.578−0.591). Kaplan−Meier curves of the high-risk predicted group showed a statistically significant difference from that of the low-risk predicted groups for all outcomes (p < 0.005; log-rank test). These findings suggest possible use of machine learning models for real-world risk assessment as a guide for observation and/or treatment decision making that may potentially lead to improved outcomes in hyperkalemic patients while retaining the benefit of life-saving therapies.

Indexed as

Heart FailureHyperkalemiaAdultAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsHumansMachine LearningPotassiumRenin-Angiotensin SystemRetrospective StudiesAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsPotassiumartificial intelligencechronic kidney diseasecongestive heart failurehyperkalemia

Identifiers

PMID36364890
PMCPMC9658112
OpenAlexW4309090358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.